Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 7/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.30 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4875677 | 0.88 | GRIN2B (0.34) | MGLLMAPTRXFP1 | |
| SCHEMBL4879016 | 0.88 | KMT2A (0.36) | DPP4 | |
| SCHEMBL4876592 | 0.88 | DPP4 (0.32) | DPP4DPP7 | |
| SCHEMBL4872630 | 0.87 | GRIN2B (0.33) | DPP4MAPT | |
| SCHEMBL4876586 | 0.86 | KCNH2 (0.34) | DPP4 | |
| SCHEMBL4876271 | 0.84 | HPGD (0.31) | MAPT | |
| SCHEMBL4877153 | 0.84 | GRIN2B (0.40) | MAPT | |
| SCHEMBL4875207 | 0.83 | GRIN2B (0.33) | MAPTRXFP1 | |
| SCHEMBL4877469 | 0.83 | GRIN2B (0.35) | — | |
| SCHEMBL3928018 | 0.82 | GRIN2B (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | DPP4 191/4885DPP7 303/4885MGLL 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.